These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Tissue-specific up-regulation of arginase I and II induced by p38 MAPK mediates endothelial dysfunction in type 1 diabetes mellitus. Pernow J; Kiss A; Tratsiakovich Y; Climent B Br J Pharmacol; 2015 Oct; 172(19):4684-98. PubMed ID: 26140333 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of Rho kinase protects from ischaemia-reperfusion injury via regulation of arginase activity and nitric oxide synthase in type 1 diabetes. Tratsiakovich Y; Kiss A; Gonon AT; Yang J; Sjöquist PO; Pernow J Diab Vasc Dis Res; 2017 May; 14(3):236-245. PubMed ID: 28183205 [TBL] [Abstract][Full Text] [Related]
18. p32-Dependent p38 MAPK Activation by Arginase II Downregulation Contributes to Endothelial Nitric Oxide Synthase Activation in HUVECs. Koo BH; Won MH; Kim YM; Ryoo S Cells; 2020 Feb; 9(2):. PubMed ID: 32046324 [TBL] [Abstract][Full Text] [Related]
19. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Ming XF; Barandier C; Viswambharan H; Kwak BR; Mach F; Mazzolai L; Hayoz D; Ruffieux J; Rusconi S; Montani JP; Yang Z Circulation; 2004 Dec; 110(24):3708-14. PubMed ID: 15569838 [TBL] [Abstract][Full Text] [Related]
20. Chronic treatment with an oral rho-kinase inhibitor restores erectile function by suppressing corporal apoptosis in diabetic rats. Li WJ; Park K; Paick JS; Kim SW J Sex Med; 2011 Feb; 8(2):400-10. PubMed ID: 20233282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]